title: Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia.
abstract: BACKGROUND
  This study was conducted to determine the treatment outcome of incompletely removed, histopathologically documented ocular surface squamous neoplasia with mitomycin-C.
  
  
  METHODS
  Through an interventional case series, 17 eyes of 17 patients presented with incompletely removed ocular surface squamous neoplasia were treated according to a protocol using two to three alternate seven-day courses of 0.04% mitomycin-C. Clinical recurrence was re-treated with the same protocol. All patients had weekly follow-up visits to the end of the treatment course, then biweekly visits for three months, and monthly visits, thereafter.
  
  
  RESULTS
  The mean+/-SD follow-up period was 30.76+/-4.4 (range: 24.5 - 41) months. Five patients (29.4%) experienced recurrence after the initial treatment; four of them responded to retreatment and were disease-free till the end of follow-up. Survival analysis with Kaplan-Meier method was performed. Taking into account four recurrences, the 41-month nonrecurrence rate was 70.6%. However, including four of five patients with recurrence who responded to retreatment, the final outcome in survival analysis was 94.1% nonrecurrence for 41 months of follow-up. All patients reported mild to moderate redness and irritation which were controlled with lubricants and mild corticosteroid eye drops. No serious ocular or systemic side effects were observed.
  
  
  CONCLUSIONS
  Point zero four percent (0.04%) mitomycin-C drop used as two to three alternate seven-day courses seems to be a safe and effective treatment for ocular surface squamous neoplasia.
authors.affiliation: Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Rahimi
authors.forename: Fateme
authors.initials: F
authors.lastname: Alipour
authors.forename: Hassan
authors.initials: H
authors.lastname: Ghazizadeh Hashemi
authors.forename: Mohammad-Naser
authors.initials: MN
authors.lastname: Hashemian
authors.forename: Ramin
authors.initials: R
authors.lastname: Mehrdad
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003230:Conjunctival Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D003315:Cornea; D004305:Dose-Response Relationship, Drug; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D013508:Ophthalmologic Surgical Procedures / Q000379:methods*; D011446:Prospective Studies; D012590:Sclera; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin